The insertion/deletion polymorphism in the ACE gene and chronic obstructive pulmonary disease

S. Simsek¹, S. Tekes¹, D. Oral¹, A. Turkyilmaz¹, B. Isik², M.R. Isik³ and H. Akkoc⁴

¹Department of Medical Biology and Genetics, Medical Faculty, Dicle University, Diyarbakir, Turkey
²Department of Biochemistry, Medical Faculty, Dicle University, Diyarbakir, Turkey
³Department of Chest Diseases and Tuberculosis, Medical Faculty, Dicle University, Diyarbakir, Turkey
⁴Department of Pharmacology, Medical Faculty, Dicle University, Diyarbakir, Turkey

Corresponding author: S. Simsek
E-mail: seldatsimsek@gmail.com

Received September 13, 2012
Accepted February 15, 2013
Published April 25, 2013
DOI http://dx.doi.org/10.4238/2013.April.25.10

ABSTRACT. An insertion/deletion (I/D) polymorphism was identified in intron 16 of the gene encoding the human angiotensin I-converting enzyme (ACE), a candidate gene for chronic obstructive pulmonary disease (COPD). We investigated the relationship between this polymorphism in the ACE gene and the risk of developing COPD. Sixty-six COPD in-patients and 40 non-smoking control individuals were recruited for this study. The distribution of ACE genotypes in these individuals was studied. The frequencies of ACE genotypes were found to be 47.0% for DD, 30.3% for ID, and 22.7% for II in the COPD group and 32.5% for DD, 47.5% for ID, and 20.0% for II in the control group. The allele frequencies were found to be 0.62% for the D allele and 0.38% for the I allele in the COPD group and 0.56% for the D allele and 0.44% for the I allele in the control group. A significant difference
was found between I and D allele frequencies (P < 0.05) of the study and control groups. Our results suggest that this ACE polymorphism may be associated with the development of COPD.

Keys words: ACE gene; Chronic obstructive pulmonary disease; Polymorphism

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) represents one of the most frequently occurring diffuse lung diseases and is influenced by both genetic and environmental factors (Ahsan et al., 2004). The World Health Organization lists COPD as the 5th most common cause of death, constituting approximately 5% of the total deaths in 2003. This number is expected to rise in the near future with the current increase in tobacco consumption in the third world being of major concern (Lee et al., 2009; Selahaddin et al., 2010).

It is known that oxidative stress is increased in COPD patients compared with either healthy subjects or smokers with similar smoking history but who have not developed COPD (MacNee, 2005; Mak, 2008; Selahaddin et al., 2010). Angiotensin I-converting enzyme (ACE), a key enzyme in the renin-angiotensin system (RAS), plays an important role in the regulation of blood pressure and serum electrolyte levels (Berdeli and Cam, 2009; Zhang et al., 2011). ACE is a component of the systemic and tissue RAS, which play an important role in the regulation of blood pressure, sodium and water homeostasis, and tissue growth. The local RAS is found in a variety of tissues, including lung and skeletal muscle, and has a diverse range of functions that are often distinct from those of the systemic RAS (Zhang et al., 2008). Functional genetic polymorphic variants have been identified in most of the components of RAS, of which the best known and studied is a polymorphism in the ACE gene.

The human ACE gene is located on chromosome 17q23, spans 21 kb, and comprises 26 exons and 25 introns (Berdeli and Cam, 2009; Zhang et al., 2011). The most widely studied polymorphism, an insertion/deletion (I/D, rs4646994), is located in intron 16. This polymorphism is characterized by the presence [insertion (I)] or absence [deletion (D)], in the intron, of a 287-bp nonsense DNA domain, resulting in 3 genotypes (II, DI, and DD) at this locus. The I/D polymorphism accounts for 20 to 50% of the variance in ACE expression or activity in blood and tissues among individuals (Rigat et al., 1992; Busquets et al., 2007; Zhang et al., 2008, 2011). ACE activity is consistently the highest in DD subjects, intermediate in ID subjects, and the lowest in II subjects (Brice et al., 1995; Ucar et al., 1997; Busquets et al., 2007; Zhang et al., 2008).

Numerous studies have been published investigating the association of the ACE I/D polymorphism with various pathophysiological conditions (Yaren et al., 2006, 2007; Gurkan et al., 2009; Namazi et al., 2010; Domingues et al., 2010; Yakut et al., 2010; Bayram et al., 2011; Zhang et al., 2011; Indrajaya, 2011; Hocher et al., 2011; Borzyszewska et al., 2012). Molecular epidemiology studies showed that ACE gene polymorphisms are closely associated with pulmonary disorders (Ahsan et al., 2004; Zhang et al., 2008). We examined the prevalence of the ACE I/D polymorphism in COPD patients.

The aim of our study was to determine whether the ACE gene I/D polymorphism can determine the course of COPD.
MATERIAL AND METHODS

Diagnosis of COPD

All pulmonary function testing was performed according to the criteria of the American Thoracic Society/European Respiratory Society task force on the standardization of lung function testing (Miller et al., 2005a,b) using the same spirometer. Three technically acceptable measurements were taken from each patient, and the highest value was included in the analyses. We performed spirometric assessments on all subjects and early reversibility testing on those who had forced expiratory volume/forced vital capacity (FEV1/FVC) <70%

The diagnosis of COPD in subjects with symptoms compatible with COPD was made when post-bronchodilator FEV1/FVC was less than 0.7. COPD was diagnosed in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (Marc et al., 2012).

Subjects and controls

Blood samples were collected from 66 COPD in-patients (42 males and 24 females; mean age: 61.23 years; SD: 11.41 years) and from 40 non-smokers (control group; 29 males and 11 females; mean age: 59.17 years; SD: 11.23 years), who were admitted to the Department of Chest Diseases and Tuberculosis, Faculty of Medicine, Dicle University. Control groups were drawn from the same population as that of the COPD subjects. This study was conducted in accordance with the Helsinki Declaration. As a standard procedure, an informed consent was obtained from each participant.

Genotyping

Genomic DNA was extracted from peripheral blood leukocytes by standard methods. The I/D polymorphism of the ACE gene was genotyped as previously described (Rigat et al., 1992). The I/D polymorphism was amplified from genomic DNA by polymerase chain reaction (PCR) with the primers 5’-CTG GAG ACC ACT CCC ATC CTT TCT-3’ and 5’-GAT GTG GCC ATC ACA TTC GTC AGA T-3’. PCR analysis was carried out in a final volume of 50 μL containing 10 pmol of each primer at 25 pmol, 2 mM of each 4 dNTPs, 50 mM KCl, 100 mM Tris-HCl, pH 8.8, 25 mM MgCl₂, and 1 U Taq Polymerase enzyme (MBI Fermentas, Germany) using a DNA thermal cycler (Techne PHC3 thermal cycler, UK). Thermal cycling was carried out using the following steps: 1 cycle at 94°C for 3 min followed by 35 cycles of 94°C for 1 min, 57°C for 1 min, and 72°C for 1 min. Final elongation included 1 cycle at 72°C for 10 min. PCR products were analyzed by electrophoresis with a 2% agarose gel and visualized with ethidium-bromide staining. The insertion allele (I) was detected as a 490-bp band and the deletion allele (D) as a 190-bp band.

Under some conditions, the ACE D allele amplified more effectively than the longer I allele, resulting in mistyping of the ID genotype as DD (Ueda et al., 1996; Kanazawa et al., 2002). To address this, the sense primer used in the PCR was replaced with an insertion-specific primer that lead to the selective amplification of the I allele, which could now be detected in previously mistyped ID genotypes. Thus, all DD genotypes were reconfirmed. For I allele-specific PCR amplification, the following primer pair was used: 5’-TGG GAC CAC
AGC GCC CGC CAC TAC-3' and 5'-TCG CCA GCC CTC CCA TGC CCA TAA-3'. Thermal cycling with this primer pair was carried out under the following conditions: 1 cycle at 94°C for 10 min followed by 30 cycles of 94°C for 30 s, 67°C for 30 s, and 72°C for 30 s. The final elongation step was 1 cycle at 72°C. The PCR products were resolved by electrophoresis on a 2% agarose gel; the resulting 335-bp DNA fragment was stained with ethidium bromide and visualized. Only the I allele produced a 335-bp fragment, while no products were detected with the DD genotype. This confirmed the absence of mistyping. No mistyping was identified.

Statistical analysis

The data were analyzed using the Mann-Whitney U-test. Allele and genotype frequencies of the I/D polymorphism of the ACE gene were obtained by direct counting. Hardy-Weinberg equilibrium was evaluated using the chi-square test. P < 0.05 was considered as significant. Statistical analyses were carried out using the statistical packages of SPSS 12.0 for Windows (SPSS Inc., USA).

RESULTS

We studied 66 in-patients with COPD and 40 non-smoking healthy control subjects. The main characteristics of the study subjects are shown in Table 1. The FEV1 value and the FEV1/FVC ratio of the COPD group were less than those of the control group (P < 0.001). The male/female ratio was similar in all groups. The genotype and allele frequencies of the ACE I/D polymorphism in COPD patients and in control groups are shown in Table 2. The ACE genotype was determined by PCR.

<table>
<thead>
<tr>
<th>Table 1. Mean characteristic of the study population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD patients (N = 66)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Gender (male/female)</td>
</tr>
<tr>
<td>Pack/years smoking*</td>
</tr>
<tr>
<td>FEV1 (% predicted)*</td>
</tr>
<tr>
<td>FEV1/FVC (% predicted)*</td>
</tr>
</tbody>
</table>

*Results are reported as means ± SD. **P value for comparison of FEV1 and FEV1/FVC levels in COPD patients and control groups.

| Table 2. Genotype and allele frequencies of the I/D polymorphism in the ACE gene. |
|-------------------------------|-------------------------------|-------------------|
| ACE I/D genotype | COPD patients (N = 66) | Non-smoker control group (N = 40) | P |
| DD | 31 (47.0%) | 13 (32.5%) | P > 0.05 |
| ID | 20 (30.3%) | 19 (47.5%) | P < 0.05 |
| II | 15 (22.7%) | 8 (20.0%) | P > 0.05 |
| Alleles |  |  |  |
| D | 82 (0.62%) | 45 (0.56%) | P > 0.05 |
| I | 50 (0.38%) | 35 (0.44%) | P > 0.05 |

Data are reported as number with percent in parentheses.

The frequencies of ACE I/D genotypes were found to be 47.0% for DD, 30.3% for ID, and 22.7% for II in COPD patients and 32.5% for DD, 47.5% for ID and 20.0% for II in the
control group (Table 2). Allele frequencies were found to be 0.62% for the D allele and 0.38% for the I allele in COPD patients and 0.56% for the D allele and 0.44% for the I allele in the control group (Table 2).

The DD and II genotypes occurred at similar frequencies in COPD and control groups with no significant differences between them (P > 0.05), while a significant difference was found between the I/D allele frequencies (P < 0.05) of study and control groups (Table 2).

**DISCUSSION**

Previous studies showed an association between *ACE* genotypes and several phenotypic characteristics of COPD. Busquets et al. (2007) showed that the DD genotype was associated with an increased risk of a smoker developing COPD and, unexpectedly, that the ID genotype is more prevalent in individuals that smoke.

Kanazawa et al. (2002) investigated the association between *ACE* polymorphisms and tissue oxygenation during exercise in patients with COPD and concluded that the *ACE* DD genotype might be associated with a disturbance in peripheral tissue oxygenation during exercise in patients with COPD.

Zhang et al. (2008) reported an association between the *ACE* gene polymorphism and exercise ventilatory response and skeletal muscle aerobic work efficiency in COPD patients. Their study indicates that the *ACE* gene may be involved in the regulation of skeletal muscle aerobic work efficiency, but is not associated with exercise ventilatory responses in COPD patients.

Lee et al. (2009) investigated the relationship between elevated ACE activity and asthma, COPD, and COPD co-morbidity and found no association between the *ACE* I/D genotypes and the risk of asthma or COPD. The *ACE* I/D genotype was not associated with a higher prevalence of ischemic heart disease or hypertension in COPD patients. Likewise, the level of physical activity among COPD patients showed no correlation with their *ACE* genotype. These data suggest that lifelong genetically elevated ACE activity is not a risk factor for asthma, COPD, or COPD co-morbidity (Lee et al., 2009).

Ahsan et al. (2004) investigated the correlation between *ACE* polymorphisms and ACE and nitric oxide levels to explore a possible genotype-phenotype association. ACE levels increased and nitric oxide levels decreased with each copy of the D allele. The genotype combination of II was significantly greater in controls as compared to COPD patients (P = 0.01; odds ratio = 2.43; 95% confidence interval = 1.21-4.87; relative risk = 2.00, 1.15-3.48) (Ahsan et al., 2004).

Hopkinson et al. (2004) investigated the relationship between the severity of skeletal muscle weakness in COPD and *ACE* genotype. They showed that in COPD patients, the D allele was associated with greater quadriceps strength compared with the I allele, and the authors suggested that this may also apply for exercise capacity (Hopkinson et al., 2004). To address this hypothesis, it is important that future studies undertake the assessment of both muscle strength and endurance in combination with muscle biopsy analysis of fiber types (Harry et al., 2004).

Kanazawa et al. (2000) suggested that the I/D polymorphism in the *ACE* gene may be associated with pulmonary hypertension evoked by exercise challenge in patients with COPD. Similarly, Tkacova et al. (2005) noted that increases in pulmonary artery pressure in patients with COPD are related to the *ACE* I/D polymorphism.

Pabst et al. (2009) noted that the ACE I allele determines a stable course of COPD.
The I allele was significantly associated with an increased risk for COPD in a dominant model, but not in a recessive or co-dominant model. Moreover, the I allele was more frequent in patients with a stable course of COPD ($P = 0.012$) than in controls. In a dominant model (II/ID vs DD) they found an even stronger association between the I allele and a stable course of COPD. We also found significant differences in the I and D allele frequencies ($P < 0.05$) in the study and control groups.

Our results suggest that \textit{ACE} polymorphisms may be associated with developing COPD. Further studies in large groups of patients with COPD are needed to address the role of \textit{ACE} polymorphisms in COPD in more detail.

\textbf{REFERENCES}


